Company news

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news

Every Regeneron Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) news

Press releases & updates

Veeva Vault CRM Selected by Regeneron

Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and...

Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation

Regeneron Reports Second Quarter 2026 Financial and Operating Results

Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus ...

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therap...

Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma

UPDATE – Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

Regeneron Named to Dow Jones Best-in-Class World Index for Global Responsibility Leadership for Seven Consecutive Years

Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial

Regeneron Reports First Quarter 2026 Financial and Operating Results

Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Th...

Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmen...

Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urtica...

Telix and Regeneron Announce Strategic Radiopharma Collaboration

Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Regeneron and Telix Announce Strategic Radiopharma Collaboration

TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Produ...

EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related M...

Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Produ...

Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

Regeneron Science Talent Search 2026 Recognizes America’s Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors fo...

Olatorepatide Obesity Treatment Licensed by Regeneron Demonstrates Positive Phase 3 Results in Chinese Patients

Regeneron Announces Investor Conference Presentation

Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ...

Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms De...

Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Ne...

Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)

PorTal Access, Inc. Appoints Industry Veteran David Snow to Board of Directors to Advance Next-Generation Oncology Vascular Access Solutions

Tessera Therapeutics Receives U.S. FDA Fast Track and Orphan Drug Designations for its Lead In Vivo Gene Editing Program TSRA-196 for the...

Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy

EYLEA HD® (aflibercept) Injection 8 mg Presentations at Angiogenesis 2026 Underscore Strength of its Clinical Profile for the Treatment o...

Regeneron Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search

BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions

Adimab Reports Strong Partnering Year for 2025

Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology

BrightInsight’s Patient App, developed with Sanofi, shows positive impact in patient treatment adherence and persistence

Regeneron to Report Fourth Quarter and Full Year 2025 Financial and Operating Results and Host Conference Call and Webcast on January 30,...

Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma